COMUNICATO STAMPA SPONSORIZZATO – Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy’s Potential for Patients with Hereditary Hemorrhagic Telangiectasia
2 Dicembre 2025 | immediapress
(Immediapress) – BASEL, Switzerland and LINCOLNSHIRE, Il., Dec. 2, 2025 /PRNewswire/ — Vaderis Therapeutics today announced that data from its randomized, double-blind, placebo-controlled, multi-center proof-of-concept study and long-term extension of engasertib (VAD044) in Hereditary H…